Phase I/II Study of LDE225 in Combination with Gemcitabine and Nab-Paclitaxel in Patients with Metastatic Pancreatic Cancer.

MLA

Pijnappel, Esther N., et al. “Phase I/II Study of LDE225 in Combination with Gemcitabine and Nab-Paclitaxel in Patients with Metastatic Pancreatic Cancer.” Cancers, vol. 13, no. 19, Sept. 2021. EBSCOhost, https://doi.org/10.3390/cancers13194869.

APA

Pijnappel, E. N., Wassenaar, N. P. M., Gurney-Champion, O. J., Klaassen, R., van der Lee, K., Pleunis-van Empel, M. C. H., Richel, D. J., Legdeur, M. C., Nederveen, A. J., van Laarhoven, H. W. M., & Wilmink, J. W. (2021). Phase I/II Study of LDE225 in Combination with Gemcitabine and Nab-Paclitaxel in Patients with Metastatic Pancreatic Cancer. Cancers, 13(19). https://doi.org/10.3390/cancers13194869

Chicago

Pijnappel, Esther N, Nienke P M Wassenaar, Oliver J Gurney-Champion, Remy Klaassen, Koen van der Lee, Marjolein C H Pleunis-van Empel, Dick J Richel, et al. 2021. “Phase I/II Study of LDE225 in Combination with Gemcitabine and Nab-Paclitaxel in Patients with Metastatic Pancreatic Cancer.” Cancers 13 (19). doi:10.3390/cancers13194869.